TSX up after index logs fresh record high close
Michael Alexander Smith, Chief Legal Officer of INSMED Inc (NASDAQ:INSM), sold 24,762 shares of common stock on September 2, 2025, in a series of transactions netting $3.49 million. The sales were executed at prices ranging from $141.16 to $145.89. The timing is notable as INSM shares are trading near their 52-week high of $146.84, having surged over 84% in the past six months. According to InvestingPro analysis, the stock’s technical indicators suggest overbought conditions.
On the same day, Smith also exercised options to acquire 12,780 shares of INSMED Inc common stock at a price of $30.46, for a total value of $389,278. These options were fully vested and exercisable. With INSM’s market capitalization now exceeding $30 billion and trading at premium multiples, InvestingPro data indicates the stock is currently overvalued. Investors can access 13 additional exclusive ProTips and a comprehensive Pro Research Report for deeper analysis of INSM’s valuation metrics and growth prospects.
In other recent news, Insmed has seen several notable developments concerning its stock evaluations and drug approvals. H.C. Wainwright significantly increased its price target for Insmed to $240 from $120, maintaining a Buy rating, following the approval of the company’s drug Brinsupri. Similarly, Truist Securities raised its price target to $139, emphasizing the potential of Brinsupri to support a multi-billion dollar opportunity. Wolfe Research also adjusted its price target to $173 from $109, highlighting the upcoming chronic rhinosinusitis without nasal polyps readout as a major catalyst for the company. Morgan Stanley raised its price target to $144, indicating confidence in the growth potential of Insmed’s drug brensocatib. Meanwhile, William Blair initiated coverage of Insmed with an Outperform rating, citing potential valuation increases from the company’s key products, including Brinsupri, Arikayce, and TPIP. These developments reflect a strong interest from analysts in Insmed’s product pipeline and future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.